Pipeline

Innovative and Differentiated Product Pipeline
Read More

Technology Platform

  • THANK-uCAR

  • CycloCAR

  • LADAR

Read More
News Center
  • CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit

    SHANGHAI, September 21, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 7th Annual CAR-TCR Summit, in Boston, Massachusetts, the Company gave an oral presentation on the North America Phase 2 clinical trial of zevorcabtagene autoleucel (“zevor-cel”, R&D code: CT053), an autologous CAR T-cell product candidate against BCMA. This multi-center, open-label, Phase 1b/2 study (NCT03915184) is being conducted to evaluate the safety and efficacy in North American patients with relapsed and/or refractory multiple myeloma (R/R MM).

    Read More
  • CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina

    SHANGHAI, September 2, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the company’s Current Good Manufacturing Practice (CGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America (“The RTP GMP Manufacturing Facility”) has started GMP production of autologous CAR T-cell products and successfully released the first GMP batch for the clinical trials.

    Read More
  • CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

    SHANGHAI, Aug 24, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results.

    Read More
  • Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

    SHANGHAI, Aug 18, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a case report, titled “Long Term Complete Response of Advanced Hepatocellular Carcinoma to Glypican-3 Specific Chimeric Antigen Receptor T-Cells plus Sorafenib, A case report”, has been published in Frontiers in Immunology (https://www.frontiersin.org/articles/10.3389/fimmu.2022.963031/full).

    Read More
  • CARsgen Appoints Dr. Hua Jiang as Executive Director

    SHANGHAI, Aug 1, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang (“Dr. Jiang”) has been appointed as Executive Director of the Company.

    Read More
  • Haematologica Publishes Results from the Investigator-Initiated Trials of CARsgen's CT053 BCMA CAR T-Cell Therapy in Multiple Myeloma

    SHANGHAI, July 19, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the results of the investigator-initiated phase I clinical trials of CT053 have been published in Haematologica (https://haematologica.org/article/view/haematol.2022.280629).

    Read More
  • CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

    SHANGHAI, June 6, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the Company presented two posters with study results for CT041, an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2). The two posters included (1) results from the multicenter Phase 1b CT041 trial in the U.S. for patients with advanced gastric and pancreatic adenocarcinoma and (2) the safety and preliminary efficacy results from the Phase Ib/II CT041 study in China for patients with advanced gastric/gastroesophageal junction adenocarcinoma.

     

    Read More
  • Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen’s CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

    SHANGHAI, May 10, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated trial of CT041 have been published in Nature Medicine (https://www.nature.com/articles/s41591-022-01800-8), which is one of the top international medical journals in the Nature Portfolio (2-year Impact Factor of 53.44).

    Read More
  • CARsgen to Present Two Clinical Trials of CT041 at ASCO Annual Meeting

    SHANGHAI, April 28, 2022 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the abstracts of CT041 have been accepted for presentations of the research updates at the 2022 annual meeting of American Society of Clinical Oncology (“2022 ASCO Annual Meeting”). The abstracts will be published soon. CT041 is an autologous CAR T-cell product candidate against Claudin18.2 (“CLDN18.2”) developed by CARsgen. The studies are named “Multicenter Phase 1b Trial in U.S. of Salvage CT041 CLDN18.2-specific Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma” and “Safety, Tolerability and Preliminary Efficacy Results in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase Ⅰb/Ⅱ Study of CLDN18.2 CAR T-cell Therapy (CT041)” respectively. The ASCO Annual Meeting is one of the most authoritative academic events in global oncology field.

     

    Read More
  • Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

    SHANGHAI, Aug 18, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a case report, titled “Long Term Complete Response of Advanced Hepatocellular Carcinoma to Glypican-3 Specific Chimeric Antigen Receptor T-Cells plus Sorafenib, A case report”, has been published in Frontiers in Immunology (https://www.frontiersin.org/articles/10.3389/fimmu.2022.963031/full).

    Read More
  • CARsgen Appoints Dr. Hua Jiang as Executive Director

    SHANGHAI, Aug 1, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang (“Dr. Jiang”) has been appointed as Executive Director of the Company.

    Read More
  • Haematologica Publishes Results from the Investigator-Initiated Trials of CARsgen's CT053 BCMA CAR T-Cell Therapy in Multiple Myeloma

    SHANGHAI, July 19, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the results of the investigator-initiated phase I clinical trials of CT053 have been published in Haematologica (https://haematologica.org/article/view/haematol.2022.280629).

    Read More
  • CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

    SHANGHAI, June 6, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the Company presented two posters with study results for CT041, an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2). The two posters included (1) results from the multicenter Phase 1b CT041 trial in the U.S. for patients with advanced gastric and pancreatic adenocarcinoma and (2) the safety and preliminary efficacy results from the Phase Ib/II CT041 study in China for patients with advanced gastric/gastroesophageal junction adenocarcinoma.

     

    Read More
  • Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen’s CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

    SHANGHAI, May 10, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated trial of CT041 have been published in Nature Medicine (https://www.nature.com/articles/s41591-022-01800-8), which is one of the top international medical journals in the Nature Portfolio (2-year Impact Factor of 53.44).

    Read More
  • CARsgen to Present Two Clinical Trials of CT041 at ASCO Annual Meeting

    SHANGHAI, April 28, 2022 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the abstracts of CT041 have been accepted for presentations of the research updates at the 2022 annual meeting of American Society of Clinical Oncology (“2022 ASCO Annual Meeting”). The abstracts will be published soon. CT041 is an autologous CAR T-cell product candidate against Claudin18.2 (“CLDN18.2”) developed by CARsgen. The studies are named “Multicenter Phase 1b Trial in U.S. of Salvage CT041 CLDN18.2-specific Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma” and “Safety, Tolerability and Preliminary Efficacy Results in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase Ⅰb/Ⅱ Study of CLDN18.2 CAR T-cell Therapy (CT041)” respectively. The ASCO Annual Meeting is one of the most authoritative academic events in global oncology field.

     

    Read More
  • CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

    SHANGHAI, June 6, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the Company presented two posters with study results for CT041, an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2). The two posters included (1) results from the multicenter Phase 1b CT041 trial in the U.S. for patients with advanced gastric and pancreatic adenocarcinoma and (2) the safety and preliminary efficacy results from the Phase Ib/II CT041 study in China for patients with advanced gastric/gastroesophageal junction adenocarcinoma.

     

    Read More
  • Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen’s CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

    SHANGHAI, May 10, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated trial of CT041 have been published in Nature Medicine (https://www.nature.com/articles/s41591-022-01800-8), which is one of the top international medical journals in the Nature Portfolio (2-year Impact Factor of 53.44).

    Read More
  • CARsgen to Present Two Clinical Trials of CT041 at ASCO Annual Meeting

    SHANGHAI, April 28, 2022 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the abstracts of CT041 have been accepted for presentations of the research updates at the 2022 annual meeting of American Society of Clinical Oncology (“2022 ASCO Annual Meeting”). The abstracts will be published soon. CT041 is an autologous CAR T-cell product candidate against Claudin18.2 (“CLDN18.2”) developed by CARsgen. The studies are named “Multicenter Phase 1b Trial in U.S. of Salvage CT041 CLDN18.2-specific Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma” and “Safety, Tolerability and Preliminary Efficacy Results in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase Ⅰb/Ⅱ Study of CLDN18.2 CAR T-cell Therapy (CT041)” respectively. The ASCO Annual Meeting is one of the most authoritative academic events in global oncology field.

     

    Read More
Join Us

Our vision is to create a world by science and technology, Making Cancer Curable

Read More